Evidence map›Paper›PMID 39979494›Full record

ArticleScientific reports2025

Disease burden of trachea, bronchus and lung cancer 1990-2021 and global trends projected to 2035.

Xin Zhang, Jing Zou, Jinghua Ning, Run Qu, Yanhong Zhao, Congcong Lv, Yi Liang, Yuzhe Zhang

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Cancer mortality in Europe in 2020, and an overview of trends since 1990.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xin Zhang *College of Basic Medical sciences, Dali University, Dali, 671000, China.
Jing Zou *Department of Respiratory Medicine, The First Affiliated Hospital of Dali University, Dali, 671000, China.
Jinghua NingCollege of Basic Medical sciences, Dali University, Dali, 671000, China.
Run QuCollege of Basic Medical sciences, Dali University, Dali, 671000, China.
Yanhong ZhaoCollege of Basic Medical sciences, Dali University, Dali, 671000, China.
Congcong LvCollege of Basic Medical sciences, Dali University, Dali, 671000, China.
Yi LiangPrincess Margaret Cancer Centre, TMDT-MaRS Centre, University Health Network, Toronto, ON, Canada.
Yuzhe ZhangCollege of Basic Medical sciences, Dali University, Dali, 671000, China. lzuzyz1568@hotmail.com.

Funding

Dali University KYBS2018012First Affiliated Hospital of Dali University DFYYB2024026Key Laboratory of Screening and Research of Resistant Plant Resources in West Yunnan APKL2101Yunnan Provincial Department of Science and Technology 202001BA070001-064, 202101BA070001-102Yunnan Provincial Key Laboratory of Entomological Biopharmaceutical R&D AG2024002
6 · The paper itself

Abstract

Tracheal, bronchial, and lung cancer (TBL) is among the most common malignancies worldwide, with persistently high incidence and mortality rates, posing a significant threat to public health. However, existing studies on TBL disease burden are often limited to specific regions or short-term trends, lacking systematic and predictive analyses. This study comprehensively evaluated the global, regional, and national burden of TBL across 204 countries and territories from 1990 to 2021, utilizing predictive models to estimate trends from 2022 to 2035. This study used data from the Global Burden of Disease (GBD) 2021 database to systematically analyze the prevalence (ASPR), incidence (ASIR), mortality (ASMR), and disability-adjusted life years (DALYs) associated with TBL. Age-standardized rates (ASR) were used to quantify disease burden. Historical trends were assessed using Joinpoint regression analysis, while ARIMA and Bayesian age-period-cohort (BAPC) models were employed to predict future trends. The study also incorporated the Sociodemographic Index (SDI) to investigate the impact of socioeconomic development on TBL burden. In 2021, the global ASPR, ASIR, ASMR, and DALYs for TBL were 37.28, 26.43, 23.50, and 638.60 per 100,000 population, respectively. From 1990 to 2021, ASPR increased slightly (0.09 per 100,000), while ASIR, ASMR, and DALYs declined by 0.07, 0.15, and 0.23 per 100,000, respectively. Regionally, the highest ASPR was observed in the high-income Asia-Pacific region (69.79 per 100,000), while East Asia recorded the highest ASIR (43.41 per 100,000) and ASMR (38.53 per 100,000). Sub-Saharan Africa had the lowest burden. Gender analysis showed that males had a significantly higher TBL burden than females, but their burden declined over the study period. In contrast, females, particularly in older age groups, experienced an increase in burden. Future predictions indicate that the overall TBL burden will decline between 2022 and 2035; however, the burden among females and older adults is projected to rise, with a marked increase in female ASPR. This study highlights the global and regional trends in TBL burden from 1990 to 2021 and provides predictions for future burden. Although the overall burden is declining, significant disparities exist across genders and regions, with East Asia and high-income North America warranting particular attention. Females and older adults are priority groups for future interventions. The findings underscore the importance of early screening, targeted interventions, and region-specific strategies to optimize public health policies, resource allocation, and tailored prevention efforts.

Indexed as

Bronchial NeoplasmsCost of IllnessGlobal Burden of DiseaseLung NeoplasmsTracheal NeoplasmsAdultAgedBayes TheoremDisability-Adjusted Life YearsFemaleGlobal HealthHumansIncidenceMaleMiddle AgedPrevalenceARIMABAPCEpidemiologyJoinpoint regression analysisRegional disparitiesTBL

Identifiers

PMID39979494
PMCPMC11842633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.